Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalasse...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

Whoami1989 Apr. 8 at 4:09 PM

$EDIT once again history repeats itself. whole world markets rise while this pathetic fpos is doing what ???

0 · Reply

Sdwg Apr. 8 at 3:42 PM

$EDIT wtf is the deal with this pos? Does the patent ruling not imply higher revenues? I must be missing something here.....geez

1 · Reply

Robert_Dempster Apr. 8 at 1:32 PM

$EDIT up up and away🚀

0 · Reply

Frankness100 Apr. 8 at 12:48 PM

$EDIT no reason not to go to 4 now.

0 · Reply

0x126 Apr. 8 at 8:35 AM

$EDIT Linus Tech Tips covering Reni results https://www.youtube.com/watch?v=OLf_pUjN-8o

1 · Reply

0x126 Apr. 8 at 8:35 AM

$EDIT https://pubmed.ncbi.nlm.nih.gov/41931047/ Reni is still giving results. Cas12a used.

0 · Reply

harryvanluik Apr. 7 at 9:03 AM

$EDIT It's happening...finally

0 · Reply

Gemola Apr. 6 at 5:16 PM

$EDIT Hold on tight.

0 · Reply

Costco_plays Apr. 6 at 4:05 PM

$EDIT $PTLE

0 · Reply

NinjaXLightning Apr. 6 at 4:03 PM

$EDIT is now starting to launch, like $SPCE and $FUBO.

0 · Reply

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Mar 9, 2026, 7:00 AM EDT - 4 weeks ago

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Feb 23, 2026, 9:00 AM EST - 6 weeks ago

Editas Medicine to Participate in Upcoming Investor Conferences

Jan 19, 2026, 2:20 AM EST - 2 months ago

Genflow Biosciences PLC Announces Directorate Change

Nov 10, 2025, 7:00 AM EST - 5 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 5 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 9, 2025, 11:01 AM EDT - 6 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 6 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 12, 2025, 4:01 PM EDT - 8 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 10 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 14, 2025, 9:31 AM EDT - 11 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 11 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 11 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 11 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 1 year ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jun 14, 2024, 3:01 AM EDT - 1 year ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

May 14, 2024, 10:00 AM EDT - 2 years ago

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 10, 2024, 6:00 AM EDT - 2 years ago

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 8, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 2, 2024, 7:00 AM EDT - 2 years ago

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 1, 2024, 8:00 AM EDT - 2 years ago

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

Apr 22, 2024, 4:31 PM EDT - 2 years ago

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Feb 28, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb 21, 2024, 7:00 AM EST - 2 years ago

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

Jan 8, 2024, 8:15 AM EST - 2 years ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 2 years ago

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 9:00 AM EST - 2 years ago

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Dec 11, 2023, 12:00 PM EST - 2 years ago

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Whoami1989 Apr. 8 at 4:09 PM

$EDIT once again history repeats itself. whole world markets rise while this pathetic fpos is doing what ???

0 · Reply

Sdwg Apr. 8 at 3:42 PM

$EDIT wtf is the deal with this pos? Does the patent ruling not imply higher revenues? I must be missing something here.....geez

1 · Reply

Robert_Dempster Apr. 8 at 1:32 PM

$EDIT up up and away🚀

0 · Reply

Frankness100 Apr. 8 at 12:48 PM

$EDIT no reason not to go to 4 now.

0 · Reply

0x126 Apr. 8 at 8:35 AM

$EDIT Linus Tech Tips covering Reni results https://www.youtube.com/watch?v=OLf_pUjN-8o

1 · Reply

0x126 Apr. 8 at 8:35 AM

$EDIT https://pubmed.ncbi.nlm.nih.gov/41931047/ Reni is still giving results. Cas12a used.

0 · Reply

harryvanluik Apr. 7 at 9:03 AM

$EDIT It's happening...finally

0 · Reply

Gemola Apr. 6 at 5:16 PM

$EDIT Hold on tight.

0 · Reply

Costco_plays Apr. 6 at 4:05 PM

$EDIT $PTLE

0 · Reply

NinjaXLightning Apr. 6 at 4:03 PM

$EDIT is now starting to launch, like $SPCE and $FUBO.

0 · Reply

Maisierocks Apr. 6 at 3:49 PM

$EDIT there is also a gap at 3.65 that will likely get filled

0 · Reply

Maisierocks Apr. 6 at 3:36 PM

$EDIT whether it goes up or not it certainly looks like a classic reverse head and shoulders formation

0 · Reply

NinjaXLightning Apr. 6 at 2:28 PM

$FUBO $SPCE Launching, $EDIT primed for launch.

0 · Reply

WallStreetBuyDip Apr. 4 at 7:46 PM

$EDIT Trading in a wide range. Currently holding around $2.65 after a bounce from $2.20. Looks like $2.20 is a key support level based on recent price action.

0 · Reply

Sdwg Apr. 3 at 1:28 PM

$HRTX penny stocks with better looking charts $BLOZF, $EDIT, $PLUG....

0 · Reply

NinjaXLightning Apr. 2 at 7:44 PM

$EDIT This is about to breakout.

1 · Reply

Realy Apr. 2 at 3:45 PM

$SGMO .5 minimum? ☕️ $XBI $EDIT

0 · Reply

DavyDaveCharts Apr. 1 at 9:53 PM

$EDIT daily, testing the AVWAP. Break and hold above, opens liquidity draw to 3.37 and possibility 4.50.

0 · Reply

Realy Apr. 1 at 4:18 PM

$LABD missed the sub-15 loading points this am but still happy with the sub-16 and 17 additions…☕️ $XBI $LABU $EDIT $SGMO

2 · Reply

Robert_Dempster Apr. 1 at 2:23 PM

$EDIT so true with patent clarity edit is an M&A target📈🐂

0 · Reply

NinjaXLightning Apr. 1 at 1:53 PM

$EDIT With patent clarity and refocused and lean capital spend, this is a potential rocket ship over the next couple of years.

0 · Reply

harryvanluik Apr. 1 at 12:24 PM

$EDIT My prediction by end of april: $4,30

0 · Reply

Market Cap	266.21M
Revenue (ttm)	40.52M
Net Income (ttm)	-160.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-395.01%
Debt to Equity Ratio	0.00

Volume	1,057,650
Avg Vol	1,685,476
Day's Range	N/A - N/A
Shares Out	97.87M
Stochastic %K	86%
Beta	2.04
Analysts	Sell
Price Target	$5.19